News
Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...
The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on ...
With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...
Wegovy is the first GLP-1 drug approved to treat adults with metabolic dysfunction-associated steatohepatitis (MASH). An ...
Novo Nordisk makes the wildly popular GLP-1 drug semaglutide which it sells under the brand name Wegovy for weight-loss and ...
The approval was based on Part 1 (72 week data) of the randomized, double-blind, placebo-controlled phase 3 ESSENCE trial.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback